Clinical Trial Update: Study of ALK-001 on the Progression of Stargardt Disease [Phase 3]

View source ↗

Summary

Alkeus Pharmaceuticals reports that the Phase 3 trial of ALK-001 for Stargardt disease is currently recruiting. The study aims to evaluate disease progression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stargardt Disease

Drugs mentioned

• ALK-001

Snippet

Sponsor: Alkeus Pharmaceuticals, Inc. | Conditions: Stargardt Disease | Phase 3 | Status: RECRUITING